Nanoparticle

Pharmaceutical and Food Industries Drive Demand for Active and Intelligent Nano-Enabled Packaging Solutions

Retrieved on: 
Thursday, November 2, 2023
Taste, Nanotechnology, Food safety, Food, Nano, Atmosphere, Nanoparticle, Light, Growth, Nanosensor, Safety, Gas, Infection, Food preservation, Fine chemical

Nano-enabled packaging is proving to be a game-changer, offering antibacterial, mechanical, and barrier properties that improve food packaging's overall quality.

Key Points: 
  • Nano-enabled packaging is proving to be a game-changer, offering antibacterial, mechanical, and barrier properties that improve food packaging's overall quality.
  • In addition to the food sector, the pharmaceutical industry is also driving the demand for nano-enabled packaging.
  • As a result, the global nano-enabled packaging market is positioned for substantial growth, driven by the food and beverage and pharmaceutical sectors.
  • With ongoing developments in packaging technology, the demand for nano-enabled packaging is expected to increase significantly during the forecast period.

Market Leaders like American Elements and Hongwu International Group Lead the Nano Copper Oxide Revolution

Retrieved on: 
Wednesday, November 1, 2023
NO3, Sodium hydroxide, Textile, Nano, Nanoparticle, Research, R, Copper(II) oxide, Electronics, Agriculture, Compound annual growth rate, Copper, Growth

The global nano copper oxide market has witnessed remarkable growth, surging to a substantial US$152.8 million in 2022.

Key Points: 
  • The global nano copper oxide market has witnessed remarkable growth, surging to a substantial US$152.8 million in 2022.
  • Nano copper oxide (CuO) nanoparticles are produced through an aqueous precipitation procedure, involving the use of various precursors like copper nitrate (Cu(NO3)2) and copper chloride (CuCI2), and sodium hydroxide (NaOH) as stabilizing agents.
  • Owing to these properties, nano copper oxide finds extensive applications in semiconductor devices, microelectronics, batteries, gas, textiles, agriculture, and biomedical tools.
  • Substantial technological advancements aimed at optimizing nano copper oxide production methods are also contributing to market expansion.

Extracellular Nanoparticles Sourced From Another Species Reverses Biological Age of Rats by More Than 50%

Retrieved on: 
Wednesday, November 1, 2023
Rat, Ageing, Plasma, Stanford University, Human, Coronavirus Scientific Advisory Board, Exosome, Pet, Diabetes, Doctor of Philosophy, Nanoparticle, Research, Stunning, Dark Ages, Rest, Biostatistics, Biology, Animal, UCLA, DNA, Pharmaceutical industry, GeroScience, Genetics, E5

MOUNTAIN VIEW, Calif., Nov. 1, 2023 /PRNewswire/ -- In a groundbreaking research paper titled "Reversal of Biological Age in Multiple Rat Organs by Young Porcine Plasma Fraction" published in GeroScience, scientists have unveiled a remarkable breakthrough in the field of aging biology. A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days. E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.

Key Points: 
  • Peer Reviewed Publication: World's first demonstration of cross species epigenetic transfer that significantly reverses biological age by Scientists at Yuvan Research.
  • A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days.
  • E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.
  • Upon final analysis by Horvath and his team, there was a remarkable 67.4% average reversal in the epigenetic age of treated elderly rats.

Extracellular Nanoparticles Sourced From Another Species Reverses Biological Age of Rats by More Than 50%

Retrieved on: 
Wednesday, November 1, 2023
Rat, Ageing, Plasma, Stanford University, Human, Coronavirus Scientific Advisory Board, Exosome, Pet, Diabetes, Doctor of Philosophy, Nanoparticle, Research, Multimedia, Stunning, Dark Ages, Rest, Biostatistics, Biology, Animal, UCLA, DNA, Pharmaceutical industry, GeroScience, Genetics, E5

MOUNTAIN VIEW, Calif., Oct. 31, 2023 /PRNewswire/ -- In a groundbreaking research paper titled "Reversal of Biological Age in Multiple Rat Organs by Young Porcine Plasma Fraction" published in GeroScience, scientists have unveiled a remarkable breakthrough in the field of aging biology. A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days. E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.

Key Points: 
  • Peer Reviewed Publication: World's first demonstration of cross species epigenetic transfer that significantly reverses biological age by Scientists at Yuvan Research.
  • A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days.
  • E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.
  • Upon final analysis by Horvath and his team, there was a remarkable 67.4% average reversal in the epigenetic age of treated elderly rats.

IDTechEx Evaluates the Emerging Materials Landscape for EMI Shielding

Retrieved on: 
Tuesday, October 31, 2023
MXenes, Vacuum, Ink, Electronics, Stainless steel, Copper, Titanium, Electromagnetic radiation, Nickel, Aluminium, Nanoparticle, Research, Printing, EMI, Tablet, Risk, Silver, SE, Thermal conductivity, Chromium, AR, Printed circuit board

When selecting a material for conformal package EMI shielding , a variety of factors need to be considered.

Key Points: 
  • When selecting a material for conformal package EMI shielding , a variety of factors need to be considered.
  • Often parametrized as shielding effectiveness (SE), higher values enable a thinner coating to be used, reducing weight and material consumption.
  • A range of solution processing methods, including spraying and inkjet printing, have been developed for EMI shielding, with all requiring conductive ink .
  • IDTechEx's report " EMI Shielding for Electronics 2024-2034: Forecasts, Technologies, Applications " provides a detailed overview of the 'EMI shielding for electronics' market, with a more detailed assessment of the outlined materials classes along with nanocarbon-containing composites, metamaterials and combined thermal interface/EMI shielding materials.

IDTechEx Evaluates the Emerging Materials Landscape for EMI Shielding

Retrieved on: 
Tuesday, October 31, 2023
MXenes, Vacuum, Ink, Electronics, Stainless steel, Copper, Titanium, Electromagnetic radiation, Nickel, Aluminium, Nanoparticle, Research, Printing, EMI, Tablet, Risk, Silver, SE, Thermal conductivity, Chromium, AR, Printed circuit board

When selecting a material for conformal package EMI shielding , a variety of factors need to be considered.

Key Points: 
  • When selecting a material for conformal package EMI shielding , a variety of factors need to be considered.
  • Often parametrized as shielding effectiveness (SE), higher values enable a thinner coating to be used, reducing weight and material consumption.
  • A range of solution processing methods, including spraying and inkjet printing, have been developed for EMI shielding, with all requiring conductive ink .
  • IDTechEx's report " EMI Shielding for Electronics 2024-2034: Forecasts, Technologies, Applications " provides a detailed overview of the 'EMI shielding for electronics' market, with a more detailed assessment of the outlined materials classes along with nanocarbon-containing composites, metamaterials and combined thermal interface/EMI shielding materials.

EQS-News: Defence Therapeutics Inc.: DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER

Retrieved on: 
Thursday, October 26, 2023
FDA, IND, City of Hope, Nivolumab, Chitosan, Beckman Research Institute, Injection, News, Defense, CDMO, Nanoparticle, BMS, City, Lymphoma, Antibody, City of Hope National Medical Center, Animal, Molecular medicine, Melanoma, Cancer, Lung cancer, Therapy, Relatlimab, Endoplasmic reticulum, Breast, Patient, Peptide, DNA, Pharmaceutical industry, Vaccine

Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications.

Key Points: 
  • Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications.
  • The AccuTOXTM molecule can eradicate cancer cells via different mechanisms including the initiation of immunogenic cells death, endoplasmic reticulum stress and by causing direct damages to DNA.
  • AccuTOXTM triggers cancer tumor regression, Defence also recently demonstrated that encapsulated AccuTOXTM with chitosan nanoparticles triggers complete tumor regression in animals with pre-established solid lymphoma.
  • Further development and expanding applications on Defence’s leading AccuTOXTM therapeutic is ongoing and further news to be released upon results.

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

Retrieved on: 
Tuesday, October 24, 2023
NEXI, Nanoparticle, T1D, Anti-CD3 monoclonal antibody, Research, JDRF, Partnership, Vaccine, Yale University

GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.

Key Points: 
  • GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.
  • The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D).
  • Combining anti-CD3 treatment with NexImmune’s injectable therapy provides the opportunity to target and modulate T1D antigen-specific T cells and potentially maintain their non-responsiveness with the goal to extend benefit and induce tolerance.
  • NexImmune’s nanoparticles have the potential to further enhance the effect of anti-CD3 through modulation of the residual T1D specific T cells.

Halliburton Announces Third Quarter 2023 Results

Retrieved on: 
Tuesday, October 24, 2023
Other Manufacturing, Technology, Other Energy, Engineering, Oil, Gas, Software, Manufacturing, Energy, Machinery, Machine Tools, Metalworking & Metallurgy, Caspian, Well, PTT Exploration and Production, ESP, Intelligence, NYSE, International, APEX, Gulf of Mexico, Pressure, Volume, HAL, Memorandum of understanding, Free cash flow, Nanoparticle, Net income, Summit, Growth, Obex, Evaluation, Hand, Completion, PTTEP, Telemetry, WDP, Operation Active Endeavour, Candid (organization), Beauty salon, Security (finance), Video game, Drug, Natural gas, Real estate, Halliburton

Halliburton Company (NYSE: HAL) announced today net income of $716 million, or $0.79 per diluted share, for the third quarter of 2023.

Key Points: 
  • Halliburton Company (NYSE: HAL) announced today net income of $716 million, or $0.79 per diluted share, for the third quarter of 2023.
  • Halliburton's total revenue for the third quarter of 2023 was $5.8 billion, flat when compared to the second quarter of 2023.
  • Operating income was $1.0 billion in the third quarter of 2023, a 3% increase when compared to the second quarter of 2023.
  • Drilling and Evaluation revenue in the third quarter of 2023 was $2.3 billion while operating income was $378 million, both flat sequentially.

New Study Using Biological Dynamics’ ExoVerita Platform Validates Exosome Detection of Early-Stage Pancreatic Ductal Adenocarcinoma (PDAC)

Retrieved on: 
Thursday, October 19, 2023
Managed Care, Research, Other Health, Oncology, Medical Devices, Infectious Diseases, Genetics, Surgery, Clinical Trials, Science, Biotechnology, Health, Other Science, Neoplasm, Survival, Biomarker, II, Oregon Health & Science University, Exosome, Detection, Cell, Nanoparticle, Biological Dynamics of Forest Fragments Project, Disease, Cancer, OHSU, Machine learning, Survival rate, Pancreatic cancer, PDAC, Pharmaceutical industry, Medical imaging, Verita

Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in Nature’s Communications Medicine titled “ Development of a Blood-Based EV Classifier for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma .” The research demonstrates the effectiveness of exosome-isolation technology in detecting Stage I and II pancreatic ductal adenocarcinoma (PDAC), using an independent validation cohort.

Key Points: 
  • Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in Nature’s Communications Medicine titled “ Development of a Blood-Based EV Classifier for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma .” The research demonstrates the effectiveness of exosome-isolation technology in detecting Stage I and II pancreatic ductal adenocarcinoma (PDAC), using an independent validation cohort.
  • Biological Dynamics’ ExoVita Pancreas assay, powered by the ExoVerita™ platform, uses the AC Electrokinetics method for exosome isolation.
  • “Driven by our Verita technology, the ExoVita test can detect challenging diseases like pancreatic cancer earlier than ever.
  • With further testing in real-world settings, we are confident our exosome enabled test will be useful for high-risk surveillance and early detection of pancreatic cancer, resulting in improved patient outcomes.”